LRMR · Larimar Therapeutics Inc

-

Please sign in to comment on LRMR

1 Comment

Admin

4 years, 1 month ago

Larimar Therapeutics, Inc is currently in a long term downtrend where the price is trading 33.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Larimar Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 95.9% to $-14M since the same quarter in the previous year.

Finally, its free cash flow grew by 2.3% to $-10M since the same quarter in the previous year.

Based on the above factors, Larimar Therapeutics, Inc gets an overall score of 2/5.

CurrencyCode	USD
ISIN	US5171251003
Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ

Target Price	20.0408
Beta	0.87
Market Cap	143M
PE Ratio	None
Dividend Yield	None

ABOUT

Larimar Therapeutics Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

LRMR · Larimar Therapeutics Inc

-

Larimar Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Larimar Therapeutics Inc using a moving average strategy